FATE THERAPEUTICS INC (FATE) Stock Research
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.
Latest price: 2.09 · Sector: Healthcare
Recent Insider Transactions
| Insider | Type | Date | Value |
|---|---|---|---|
| Adawi Kamal | sell | 2026-11-03 | 13524.69 |
| TAHL CINDY | sell | 2026-08-04 | 95405.32 |
| Valamehr Bahram | sell | 2026-08-04 | 108100.83 |
| Valamehr Bahram | sell | 2026-05-20 | 54482.16 |
| TAHL CINDY | sell | 2026-05-20 | 48083.61 |
| Valamehr Bahram | sell | 2026-01-09 | 5557.45 |
| TAHL CINDY | sell | 2026-01-09 | 11275.17 |